masitinib + docetaxel

Masitinib + docetaxel is a combination therapy evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly in patients who are eligible for docetaxel and have not responded to hormone therapy. **Masitinib** is an oral small molecule tyrosine kinase inhibitor (TKI) primarily targeting mast cells and macrophages by inhibiting several kinases, thereby modulating the tumor microenvironment and immune response. **Docetaxel** is an established intravenous chemotherapy drug (a taxane) that disrupts microtubule function, inhibiting cell division. This combination aims to slow disease progression; masitinib is postulated to enhance the effect of standard chemotherapy with docetaxel by affecting tumor biology through its role in the tumor microenvironment. Clinical trials have shown that this combination can yield a statistically significant reduction in the risk of progression or death in mCRPC patients with lower baseline alkaline phosphatase (ALP) levels[1][2][3][4].